A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.

被引：2
|
作者：
Garcia, Agustin A.
Hays, John L.
Cote, Gregory Michael
Becerra, Carlos
Langleben, Adrian
Lau, Susie K.
Roman, Lynda D.
McCormick, Colleen Catherine
Richards, Donald A.
Braiteh, Fadi S.
Yimer, Habte Aragaw
Richey, Stephen Lane
Edenfield, William Jeffery
Kossler, Kimiko
Hume, Stephanie
Li, Youzhi
Hitron, Matthew
Li, Chiang
机构：
[1] Univ Southern Calif, Los Angeles Cty Hosp, Los Angeles, CA USA
[2] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[5] St Marys Hosp, Westmount, PQ, Canada
[6] McGill Univ, Montreal, PQ, Canada
[7] Johns Hopkins Univ Hosp, Portland, OR USA
[8] McKesson Specialty Hlth, Tyler Canc Ctr, US Oncol Res, Houston, TX USA
[9] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
[10] Texas Oncol, Tyler, TX USA
[11] McKesson Specialty Hlth, Texas Oncol, US Oncol Network, Houston, TX USA
[12] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[13] Boston Biomed Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5578
引用
收藏
页数：3
相关论文
共 50 条
  • [41] PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer.
    Oldenburg, Jan
    Normann, Marius
    Turzer, Martin
    Solheim, Olesya
    Diep, Lien My
    Gajdzik, Beata
    Rud, Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.
    Shah, Payal D.
    Zarrin, Haley
    Wethington, Stephanie
    Latif, Nawar
    Martin, Lainie
    Rodriguez, Diego
    Elkins, Katie
    Giuntoli, Robert
    Burger, Robert
    Tanyi, Janos
    Morgan, Mark
    Domchek, Susan M.
    Gailliard, Stephanie
    Armstrong, Deborah K.
    Simpkins, Fiona
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 75 - 75
  • [43] Feasibility of bevacizumab combined with gemcitabine in treatment of platinum-resistant epithelial ovarian cancer.
    Kogiku, Ai
    Nagao, Shoji
    Suzuki, Kazuhiro
    Yamamoto, Kasumi
    Senda, Tokihiro
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Sudo, Tamotsu
    Yamaguchi, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S145 - S145
  • [45] A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum-resistant ovarian cancer
    Odunsi, K.
    Ghamande, S.
    Macfee, M.
    Yu, A. Yin Chieh
    Lele, S. B.
    Rodabaugh, K. J.
    Thomas, B.
    Zamboni, W. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer
    Blank, S.
    Mahdi, H.
    Tehrani, O.
    Ghamande, S.
    Jain, S.
    Nicacio, L.
    Soumaoro, I.
    O'Malley, D. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S646 - S646
  • [47] Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial
    Coleman, Robert L.
    Handley, Katelyn F.
    Burger, Robert
    Dal Molin, Graziela Zibetti
    Stagg, Robert
    Sood, Anil K.
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 386 - 391
  • [48] PHASE IB DOSE ESCALATION TRIAL OF THE ORAL HEDGEHOG INHIBITOR SONIDEGIB (LDE225) AND WEEKLY PACLITAXEL IN PLATINUM RESISTANT OVARIAN CANCER
    Arend, R.
    Bae, S.
    Alvarez, R.
    Straughn, J. M.
    Bevis, K.
    Estes, J.
    Sirles, T.
    Burton, A.
    Landen, C.
    Leath, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 233 - 233
  • [49] A phase II trial of voreloxin in women with platinum-resistant ovarian cancer
    Hirte, H. W.
    McGuire, W.
    Edwards, R.
    Husain, A.
    Hoskins, P.
    Michels, J.
    Matulonis, U.
    Sexton, C.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
    McNeish, I. A.
    Moreno, V.
    Jayson, G.
    Roxburgh, P.
    Barretina Ginesta, M. P.
    Garcia-Donas, J.
    Anton Torres, A.
    Michael, A.
    Brown, R.
    Krige, D.
    Bendall, J.
    Di Genova, G.
    McElwaine-Johnn, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 421 - 421
12345